Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308451842> ?p ?o ?g. }
- W4308451842 endingPage "e002477" @default.
- W4308451842 startingPage "e002477" @default.
- W4308451842 abstract "Tocilizumab showed trends for improving skin fibrosis and prevented progression of lung fibrosis in systemic sclerosis (SSc) in randomised controlled clinical trials. We aimed to assess safety and effectiveness of tocilizumab in a real-life setting using the European Scleroderma Trial and Research (EUSTAR) database.Patients with SSc fulfilling the American College of Rheumatology (ACR)/EULAR 2013 classification criteria, with baseline and follow-up visits at 12±3 months, receiving tocilizumab or standard of care as the control group, were selected. Propensity score matching was applied. Primary endpoints were the modified Rodnan skin score (mRSS) and FVC at 12±3 months compared between the groups. Secondary endpoints were the percentage of progressive/regressive patients for skin and lung at 12±3 months.Ninety-three patients with SSc treated with tocilizumab and 3180 patients with SSc with standard of care fulfilled the inclusion criteria. Comparison between groups did not show significant differences, but favoured tocilizumab across all predefined primary and secondary endpoints: mRSS was lower in the tocilizumab group (difference -1.0, 95% CI -3.7 to 1.8, p=0.48). Similarly, FVC % predicted was higher in the tocilizumab group (difference 1.5 (-6.1 to 9.1), p=0.70). The percentage of progressive/regressive patients favoured tocilizumab over controls. These results were robust regarding the sensitivity analyses. Safety analysis confirmed previously reported adverse event profiles.Although this large, observational, controlled, real-life EUSTAR study did not show significant effectiveness of tocilizumab on skin and lung fibrosis, the consistency of direction of all predefined endpoints generates hypothesis for potential effectiveness in a broader SSc population." @default.
- W4308451842 created "2022-11-12" @default.
- W4308451842 creator A5002907433 @default.
- W4308451842 creator A5009125671 @default.
- W4308451842 creator A5009236113 @default.
- W4308451842 creator A5013335098 @default.
- W4308451842 creator A5013941152 @default.
- W4308451842 creator A5013946505 @default.
- W4308451842 creator A5018486655 @default.
- W4308451842 creator A5021325261 @default.
- W4308451842 creator A5022053818 @default.
- W4308451842 creator A5028545816 @default.
- W4308451842 creator A5031336901 @default.
- W4308451842 creator A5033091024 @default.
- W4308451842 creator A5034268777 @default.
- W4308451842 creator A5035816121 @default.
- W4308451842 creator A5038198555 @default.
- W4308451842 creator A5040092699 @default.
- W4308451842 creator A5041057910 @default.
- W4308451842 creator A5044812962 @default.
- W4308451842 creator A5045319089 @default.
- W4308451842 creator A5046636617 @default.
- W4308451842 creator A5047316251 @default.
- W4308451842 creator A5048430823 @default.
- W4308451842 creator A5050109776 @default.
- W4308451842 creator A5050821878 @default.
- W4308451842 creator A5056012711 @default.
- W4308451842 creator A5057084369 @default.
- W4308451842 creator A5058230766 @default.
- W4308451842 creator A5059359523 @default.
- W4308451842 creator A5059618465 @default.
- W4308451842 creator A5060393248 @default.
- W4308451842 creator A5060654505 @default.
- W4308451842 creator A5060748469 @default.
- W4308451842 creator A5065180151 @default.
- W4308451842 creator A5069066410 @default.
- W4308451842 creator A5070813771 @default.
- W4308451842 creator A5075788011 @default.
- W4308451842 creator A5077973925 @default.
- W4308451842 creator A5084426712 @default.
- W4308451842 creator A5090885390 @default.
- W4308451842 date "2022-11-01" @default.
- W4308451842 modified "2023-10-18" @default.
- W4308451842 title "Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort" @default.
- W4308451842 cites W1823119911 @default.
- W4308451842 cites W1985651745 @default.
- W4308451842 cites W1993540575 @default.
- W4308451842 cites W2008442280 @default.
- W4308451842 cites W2036193982 @default.
- W4308451842 cites W2046492421 @default.
- W4308451842 cites W2047163949 @default.
- W4308451842 cites W2068144165 @default.
- W4308451842 cites W2095975942 @default.
- W4308451842 cites W2106211249 @default.
- W4308451842 cites W2110217426 @default.
- W4308451842 cites W2118561596 @default.
- W4308451842 cites W2130052733 @default.
- W4308451842 cites W2130839876 @default.
- W4308451842 cites W2131895585 @default.
- W4308451842 cites W2152849583 @default.
- W4308451842 cites W2164096595 @default.
- W4308451842 cites W2168458505 @default.
- W4308451842 cites W2275737843 @default.
- W4308451842 cites W2318935314 @default.
- W4308451842 cites W2320758849 @default.
- W4308451842 cites W2345770885 @default.
- W4308451842 cites W2347093301 @default.
- W4308451842 cites W2396463232 @default.
- W4308451842 cites W2408925540 @default.
- W4308451842 cites W2470147424 @default.
- W4308451842 cites W2508060872 @default.
- W4308451842 cites W2549071917 @default.
- W4308451842 cites W2738265025 @default.
- W4308451842 cites W2750520295 @default.
- W4308451842 cites W2781304682 @default.
- W4308451842 cites W2807354082 @default.
- W4308451842 cites W2922032370 @default.
- W4308451842 cites W2936745692 @default.
- W4308451842 cites W2945521814 @default.
- W4308451842 cites W2999054805 @default.
- W4308451842 cites W3004351863 @default.
- W4308451842 cites W3081624185 @default.
- W4308451842 cites W3089161952 @default.
- W4308451842 doi "https://doi.org/10.1136/rmdopen-2022-002477" @default.
- W4308451842 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36328401" @default.
- W4308451842 hasPublicationYear "2022" @default.
- W4308451842 type Work @default.
- W4308451842 citedByCount "4" @default.
- W4308451842 countsByYear W43084518422023 @default.
- W4308451842 crossrefType "journal-article" @default.
- W4308451842 hasAuthorship W4308451842A5002907433 @default.
- W4308451842 hasAuthorship W4308451842A5009125671 @default.
- W4308451842 hasAuthorship W4308451842A5009236113 @default.
- W4308451842 hasAuthorship W4308451842A5013335098 @default.
- W4308451842 hasAuthorship W4308451842A5013941152 @default.
- W4308451842 hasAuthorship W4308451842A5013946505 @default.
- W4308451842 hasAuthorship W4308451842A5018486655 @default.
- W4308451842 hasAuthorship W4308451842A5021325261 @default.